Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 4401 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 73 |
| 4402 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 54 |
| 4403 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 61 |
| 4404 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 70 |
| 4405 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 59 |
| 4406 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 68 |
| 4407 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 4408 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 60 |
| 4409 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 55 |
| 4410 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 54 |
| 4411 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 56 |
| 4412 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 54 |
| 4413 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 44 |
| 4414 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 55 |
| 4415 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 67 |
| 4416 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 53 |
| 4417 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 59 |
| 4418 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 30 |
| 4419 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 34 |
| 4420 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 58 |
| 4421 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 66 |
| 4422 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 35 |
| 4423 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 5 |
| 4424 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 65 |
| 4425 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 61 |
| 4426 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 49 |
| 4427 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 64 |
| 4428 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 61 |
| 4429 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 39 |
| 4430 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 45 |
| 4431 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 59 |
| 4432 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 4433 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 4434 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 59 |
| 4435 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 1 |
| 4436 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 53 |
| 4437 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 14 |
| 4438 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 15 |
| 4439 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 58 |
| 4440 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 66 |
| 4441 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 61 |
| 4442 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 72 |
| 4443 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 51 |
| 4444 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 53 |
| 4445 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 39 |
| 4446 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 42 |
| 4447 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 52 |
| 4448 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 55 |
| 4449 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 69 |
| 4450 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 4451 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 64 |
| 4452 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 58 |
| 4453 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 37 |
| 4454 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Poland | 72 |
| 4455 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 64 |
| 4456 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 45 |
| 4457 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 67 |
| 4458 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 67 |
| 4459 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 61 |
| 4460 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 36 |
| 4461 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 34 |
| 4462 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 48 |
| 4463 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 60 |
| 4464 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 48 |
| 4465 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 35 |
| 4466 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 42 |
| 4467 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 59 |
| 4468 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 20 |
| 4469 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 58 |
| 4470 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 44 |
| 4471 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2020 | Standard Therapy | Germany | 30 |
| 4472 | Apheresis | Allogeneic | Acute Myeloid Leukemia; Myelodysplastic Syndrome | Hematology | 2020 | Standard Therapy | Poland | 64 |
| 4473 | Apheresis | Allogeneic | Acute Undifferentiated Leukemia | Hematology | 2020 | Standard Therapy | Poland | 31 |
| 4474 | Apheresis | Autologous | Amyloid Light-Chain Amyloidosis | Hematology | 2020 | Standard Therapy | Germany | 62 |
| 4475 | Apheresis | Autologous | Amyloidosis | Hematology | 2020 | Standard Therapy | Germany | 58 |
| 4476 | Apheresis | Allogeneic | Anaplastic Large Cell Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 8 |
| 4477 | Apheresis | Allogeneic | Aplastic Anemia | Hematology | 2020 | Standard Therapy | Poland | 12 |
| 4478 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 29 |
| 4479 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2020 | Standard Therapy | Germany | 58 |
| 4480 | Apheresis | Autologous | B-Cell Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 68 |
| 4481 | Apheresis | Autologous | B-Cell Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 70 |
| 4482 | Apheresis | Autologous | B-Cell Lymphoma – Second Primary Central Nervous System Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 70 |
| 4483 | Apheresis | Autologous | B-Cell Non-Hodgkin Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 57 |
| 4484 | Apheresis | Autologous | Bone Tumor | Hematology | 2020 | Standard Therapy | Germany | 28 |
| 4485 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 49 |
| 4486 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 74 |
| 4487 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 67 |
| 4488 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 58 |
| 4489 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 61 |
| 4490 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 56 |
| 4491 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 47 |
| 4492 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 73 |
| 4493 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 62 |
| 4494 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 57 |
| 4495 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 44 |
| 4496 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2020 | Standard Therapy | Poland | 62 |
| 4497 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2020 | Standard Therapy | Poland | 66 |
| 4498 | Apheresis | Allogeneic | Chronic Neutrophilic Leukemia | Hematology | 2020 | Standard Therapy | Germany | 31 |
| 4499 | Apheresis | Allogeneic | Diffuse Large B-Cell Lymphoma | Hematology | 2020 | Standard Therapy | Poland | 63 |
| 4500 | Apheresis | Autologous | Diffuse Large B-Cell Lymphoma | Hematology | 2020 | Standard Therapy | Germany | 68 |